0.05Open0.05Pre Close91 Volume1.07K Open Interest5.50Strike Price405.00Turnover54.10%IV13.32%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.1287Delta0.4315Gamma162.67Leverage Ratio-0.0042Theta0.0002Rho20.94Eff Leverage0.0019Vega
Fortuna Silver Mines Stock Discussion
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology (CLVS.US)$ +11.3%, $Cardiff Oncology (CRDF.US)$ +9%, $Immatics (IMTX.US)$ +8.3%, $IDEAYA Biosciences (IDYA.US)$ +8%, $Lyra Therapeutics (LYRA.US)$ +5.7%, $POINT Biopharma (PNT.US)$ +5.7%, $Edgewise Therapeutics (EWTX.US)$ +4.7%, $Concert Pharmaceuticals (CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals (DCPH.US)$ +3.2%, $Veracyte (VCYT.US)$ +2.6%, $SpringWorks Therapeutics (SWTX.US)$ +2.3%, ...
• $Kohl's Corp (KSS.US)$ +10.4% (Board of Directors enters into three-week exclusive negotiations with $Franchise (FRG.US)$)
• $Gitlab (GTLB.US)$ +8.5% (In reaction to earnings)
• $United Natural Foods (UNFI.US)$ +6.9% (In reaction to earnings)
• $Dave & Buster's Entertainment (PLAY.US)$ +6.3% (In reaction to earnings)
• $G-III Apparel Group (GIII.US)$ +5.6% (In reaction to earnings)
• $HealthEquity (HQY.US)$ +4.2% (In reaction to ea...
• $SailPoint Technologies (SAIL.US)$ +30% (confirms agreement to be acquired by Thoma Bravo for $6.9 bln; stockholders to receive $65.25 per share in cash)
• $Veru Inc (VERU.US)$ +28.9% (Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy)
• $Affimed NV (AFMD.US)$ +12.9% (Presents Upda...
No comment yet